journal
Journals International Clinical Psychop...

International Clinical Psychopharmacology

https://read.qxmd.com/read/38640201/sex-controlled-differences-in-sertraline-and-citalopram-efficacies-in-major-depressive-disorder-a-randomized-double-blind-trial
#1
JOURNAL ARTICLE
Ahmad Shamabadi, Hanie Karimi, Mohammad Ali Fallahzadeh, Salar Vaseghi, Razman Arabzadeh Bahri, Bita Fallahpour, Amir Hossein Abdolghaffari, Shahin Akhondzadeh
To investigate the response to antidepressants while controlling for sex, which has been controversial, 92 outpatient males and females with major depressive disorder were assigned to sertraline (100 mg/day) or citalopram (40 mg/day) in two strata and were assessed using Hamilton depression rating scale (HDRS) scores and brain-derived neurotrophic factor (BDNF), interleukin (IL)-6 and cortisol serum levels in this 8-week, randomized, parallel-group, double-blind clinical trial. Data of 40 sertraline and 40 citalopram recipients with equal representation of males and females assigned to each medication were analyzed, while their baseline characteristics were not statistically different (P > 0...
April 18, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38568112/differential-effects-of-sertraline-and-cognitive-behavioural-therapy-on-behavioural-inhibition-in-patients-with-obsessive-compulsive-disorder
#2
JOURNAL ARTICLE
Jemma E Reid, Luca Pellegrini, Lynne Drummond, Yana Varlakova, Sonia Shahper, David S Baldwin, Christopher Manson, Samuel R Chamberlain, Trevor W Robbins, David Wellsted, Naomi A Fineberg
Patients with obsessive compulsive disorder (OCD) randomised to sertraline, manualised cognitive behavioural therapy (CBT), or combination (sertraline + CBT), underwent cognitive assessment. Cognitive testing was conducted at baseline and at week 16. The stop signal reaction time task (SSRT) was used to evaluate motor impulsivity and attentional flexibility was evaluated using the intra/extra-dimensional set shifting task. Paired-samples t-tests or nonparametric variants were used to compare baseline and posttreatment scores within each treatment group...
April 2, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38477521/recent-updates-on-treatment-patterns-in-patients-with-treated-attention-deficit-hyperactivity-disorders-from-a-nationwide-real-world-database-in-south-korea
#3
JOURNAL ARTICLE
Yoon Cho, Ah-Young Kim, Sukhyang Lee, Hankil Lee
The prevalence of attention-deficit/hyperactivity disorder (ADHD) is steadily increasing across Korea. We analyzed ADHD patients with ADHD medications (Rx) characteristics and treatment patterns compared to patients without Rx and identified the differences between pediatric-/adult- and active-/transient-patients with Rx. Using a nationwide claims dataset from 2020 to 2021, we conducted a prevalence-based cross-sectional study and analyzed the recent patients' characteristics and patterns among ADHD patients...
March 11, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38465918/parasomnia-induced-by-lemborexant-a-case-report
#4
JOURNAL ARTICLE
Toshinori Nakamura, Yusuke Arai, Tetsuya Hagiwara, Ryosuke Kitoh, Daimei Sasayama, Shinsuke Washizuka
Lemborexant, an orexin receptor antagonist, is effective not only for sleep disorders but also for preventing and treating delirium. To date, no complex sleep-related behaviors due to lemborexant have been reported. Herein, we present the case of a 69-year-old male patient who was hospitalized for oral floor and tongue cancer and developed delirium after surgery; however, upon lemborexant dosage increase, used to treat insomnia, he developed abnormal nocturnal behavior. This symptom rapidly improved when lemborexant was discontinued...
March 11, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38381918/evaluating-the-influence-of-nonproblematic-alcohol-intake-on-the-outcome-of-major-depression
#5
JOURNAL ARTICLE
Víctor Navarro, Joana Guarch, Ilham Boulahfa, Laia Tardón, Amadeu Obach, Cristóbal Gastó, Manel Vila-Vidal
The effect of light or moderate alcohol intake on the outcome of patients with major depression taking antidepressants is a question that remains unanswered. The main objective of this study was to assess the association between light or moderate alcohol consumption and the acute response (efficacy and tolerability) to pharmacological treatment in unipolar major depression. Efficacy and tolerability analyses compared 8-week outcomes between three subgroups, abstainers, light drinkers and moderate drinkers, of patients with major depression using a prospective naturalistic single-blind design...
February 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38381905/micronized-ultramicronized-palmitoylethanolamide-improves-depression-and-fatigue-in-coronavirus-disease-2019-covid-19-survivors
#6
JOURNAL ARTICLE
Aurora Merolla, Rebecca De Lorenzo, Giacomo Paolazzi, Sara Critelli, Mariagrazia Palladini, Sarah Damanti, Giordano Vitali, Valentina Canti, Marta Cilla, Sabina Martinenghi, Elisabetta Falbo, Marica Ferrante, Jacopo Castellani, Giacomo Pacioni, Cristiano Magnaghi, Anna Fumagalli, Mario G Mazza, Francesco Benedetti, Patrizia Rovere-Querini
Coronavirus disease 2019 (COVID-19) may lead to neuropsychiatric sequelae. Palmitoylethanolamide (PEA) is an anti-inflammatory and neuroprotective amide used in depressive syndromes. Here we investigate whether micronized/ultramicronized (m/um) PEA improves neuropsychiatric sequelae in COVID-19 survivors. Patients evaluated at our post-COVID-19 outpatient clinic between February and August 2021 and presenting neuropsychiatric manifestations (n = 98) were offered treatment with m/umPEA 600 mg twice daily for 3 months...
February 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38381901/prospective-comparative-pilot-study-of-maintenance-treatment-in-comorbid-bipolar-disorders-with-post-traumatic-stress-disorder
#7
JOURNAL ARTICLE
Hernán F Guillen-Burgos, Juan F Gálvez-Flórez, Sergio Moreno-Lopez, Angela T H Kwan, Roger S McIntyre
There is limited real-world evidence that evaluates the impact of monotherapy vs. combination therapy as a maintenance treatment in comorbid post-traumatic stress disorder (PTSD) in bipolar disorder (BD). Our aim was to compare lithium vs. lithium plus quetiapine in maintenance treatment in a sample of comorbid BD with PTSD. An exploratory, comparative pilot study over a 28-week period in 34 comorbid BD with PTSD patients was performed to compare monotherapy (n = 18) vs. combination therapy (n = 16) during maintenance treatment...
February 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38381900/the-impact-of-efficacy-of-long-acting-injectable-antipsychotics-on-caregivers-burden-of-patients-with-schizophrenia
#8
JOURNAL ARTICLE
Enrico Capuzzi, Cecilia Quitadamo, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli
No abstract text is available yet for this article.
February 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38381917/metabolic-syndrome-and-its-relation-to-antipsychotic-polypharmacy-in-schizophrenia-schizoaffective-and-bipolar-disorders
#9
JOURNAL ARTICLE
Karim Abdel Aziz, Hind Mohd Ahmed, Emmanuel Stip, Dina Aly El-Gabry
The risk of metabolic syndrome (MetS) has been attributed to antipsychotic use in psychiatric patients. To date, there is limited data on the relationship between antipsychotic polypharmacy and MetS in patients with schizophrenia, schizoaffective disorder and bipolar disorder. Therefore, we aimed to investigate the rate of MetS in patients with these disorders receiving antipsychotic monotherapy and polypharmacy. We conducted a cross-sectional study on patients seen between January 2017 and December 2020, collecting data on the class, type, route of administration and number of antipsychotics received...
February 13, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38381913/towards-a-replicable-protocol-to-identify-patients-with-psychiatric-disorders-at-higher-risk-of-developing-dementia
#10
JOURNAL ARTICLE
Veronika Matuskova, Martin Vyhnalek
No abstract text is available yet for this article.
February 13, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38299624/uk-medical-cannabis-registry-a-case-series-analyzing-clinical-outcomes-of-medical-cannabis-therapy-for-generalized-anxiety-disorder-patients
#11
JOURNAL ARTICLE
Adam Li, Simon Erridge, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Matthieu Crews, Lorna Donnelly, Muhammad Imran, Laura Korb, Gracia Mwimba, Simmi Sachdeva-Mohan, James J Rucker, Mikael H Sodergren
This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety disorder (GAD) prescribed a homogenous selection of cannabis-based medicinal products (CBMPs). Patients prescribed Adven CBMPs (Curaleaf International, UK) for GAD were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in patient-reported outcome measures (PROMs) from baseline up to 12 months, including GAD-7, Single-Item Sleep Quality Scale (SQS), and EQ-5D-5L...
February 2, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38277187/safety-and-tolerability-of-cariprazine-for-the-adjunctive-treatment-of-major-depressive-disorder-a-pooled-analysis-of-phase-2b-phase-3-clinical-trials
#12
JOURNAL ARTICLE
Michael E Thase, Paul P Yeung, Ludmyla Rekeda, Meng Liu, Shane Varughese
To characterize the safety and tolerability of adjunctive cariprazine in patients with major depressive disorder (MDD) and inadequate response to monotherapy antidepressant treatment (ADT). Post hoc analyses evaluated pooled data from 2 fixed-dose phase 3 cariprazine studies (1.5 and 3 mg/d [approved doses for MDD]). In a separate safety analysis, cariprazine 0.1-4.5 mg/d was evaluated using data from the 2 fixed-dose trials plus 3 flexible-dose studies grouped by modal-daily dose. In the pooled phase 3 studies (placebo = 503, 1...
January 25, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38527157/stroke-covid-19-and-other-somatic-aspects-of-psychiatric-disorders-treatments
#13
JOURNAL ARTICLE
Alessandro Serretti
No abstract text is available yet for this article.
May 1, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38299310/modulating-factors-in-mood-disorders-treatment
#14
JOURNAL ARTICLE
Alessandro Serretti
No abstract text is available yet for this article.
March 1, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38277272/is-pilates-effective-in-improving-depressive-disorders-a-comprehensive-overview
#15
JOURNAL ARTICLE
Francesca Legnani, Lorenzo Tassi, Teresa Surace, Enrico Capuzzi, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli
Depressive disorders are disabling conditions that account for high social costs. Pilates demonstrated to have several beneficial effects on health. Objective of this manuscript was to systematically review the literature about the effects of Pilates on depressive disorders. A bibliographic search was conducted in the main database sources (Pubmed, Medline, and Scopus). The inclusion criteria consisted of articles written in English language about the effectiveness of Pilates on depressive symptoms. Most of included studies are randomized controlled trials (10 out of 12)...
January 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38277263/differed-spontaneous-dissociative-symptoms-following-the-use-of-esketamine-intranasal-spray-in-a-patient-suffering-from-treatment-resistant-depression-a-case-report
#16
JOURNAL ARTICLE
Louis Chevalier, Samuel Bulteau, Louis Cheval, Jalal Charron, Anne Sauvaget, Andrew Laurin
Intranasal esketamine is used in France for treatment-resistant depression. Dissociative symptoms are common side effects during treatment sessions. We report a case of delayed spontaneous dissociative symptoms following esketamine administration. A 20-year-old female with treatment-resistant depression received esketamine treatment. Dissociative symptoms occurred during sessions and persisted at a distance, often accompanied by anxiety. Delayed dissociative phenomena disappeared within the fourth week of treatment by esketamine...
January 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38266159/case-report-and-systematic-review-of-cerebellar-vermis-alterations-in-psychosis
#17
JOURNAL ARTICLE
Nicola Dusi, Cecilia Maria Esposito, Giuseppe Delvecchio, Cecilia Prunas, Paolo Brambilla
INTRODUCTION: Cerebellar alterations, including both volumetric changes in the cerebellar vermis and dysfunctions of the corticocerebellar connections, have been documented in psychotic disorders. Starting from the clinical observation of a bipolar patient with cerebellar hypoplasia, the purpose of this review is to summarize the data in the literature about the association between hypoplasia of the cerebellar vermis and psychotic disorders [schizophrenia (SCZ) and bipolar disorder (BD)]...
January 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38261431/immunomodulatory-options-for-neurodevelopmental-spectrum-conditions-are-we-there-yet
#18
JOURNAL ARTICLE
Martina Arenella
About 3-7% of the worldwide population is diagnosed with a neurodevelopmental condition, including autism and attention-deficit hyperactivity disorder. Nonetheless, the aetiology of these conditions is unclear and support options are limited or not effective for all those diagnosed. Cumulating evidence, however, supports a role of the immune system in neurodevelopment, and immune dysregulations have been implicated in neurodevelopmental atypicalities. This knowledge offers tremendous opportunities, especially the possibility to adopt immunomodulatory compounds, which are already available and safe to use, for the management of neurodevelopmental difficulties...
January 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38261424/change-in-absolute-neutrophil-count-after-covid-19-infection-in-patients-using-clozapine-versus-other-antipsychotics
#19
JOURNAL ARTICLE
Seong Hoon Jeong, Mi Gyung Lee, Yong Sik Kim, In Won Chung
It was reported that patients who contracted COVID-19 while taking clozapine exhibited a distinct hematological response. However, the absence of control groups made it difficult to attribute it to clozapine. The changes in absolute neutrophil counts (ANCs) during the 4 weeks after COVID-19 infection were compared between the two groups of patients with severe mental illnesses (SMIs) (49 patients using clozapine and 54 using other antipsychotics) using generalized additive modeling. Although the pattern of a transient drop in ANC followed by gradual recovery could be demonstrated in both groups, it was more pronounced in the clozapine group (P = 0...
January 22, 2024: International Clinical Psychopharmacology
https://read.qxmd.com/read/38215015/it-is-ethical-to-publish-successful-case-reports-about-patient-with-treatment-resistant-depression
#20
JOURNAL ARTICLE
Anne Sauvaget, Samuel Bulteau, Andrew Laurin
No abstract text is available yet for this article.
January 15, 2024: International Clinical Psychopharmacology
journal
journal
29324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.